ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

サフィナミド

Safinamide

HCID 131682
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
133865-89-1
標準SMILES
C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O
InChIKey
NEMGRZFTLSKBAP-LBPRGKRZSA-N
分子式
C17H19FN2O2
平均分子量
302.34 g/mol
単同位体質量
302.14305602

概要

Safinamide is an amino acid amide.

名称と識別子

優先名称
Safinamide
IUPAC
(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
現地名
サフィナミド
英語名
Safinamide
分子式
C17H19FN2O2
分子量
302.34

名称と別名

Safinamide133865-89-1(2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamideEMD 1195686SafinamidaFce-26743EMD-119568690ENL74SIG2-(4-(3-Fluorobenzyloxy)benzylamino)propionamideDTXCID701436700DTXSID601010282safinamidum
名称をさらに表示
サフィナミド(S)-2-[[4-[(3-フルオロベンジル)オキシ]ベンジル]アミノ]プロピオンアミド(2S)-2-[({4-[(3-フルオロフェニル)メトキシ]フェニル}メチル)アミノ]プロパンアミドNα-[4-(3-フルオロベンジルオキシ)ベンジル]-L-アラニンアミド(S)-2-[[[4-[(3-フルオロフェニル)メトキシ]フェニル]メチル]アミノ]プロパンアミド(S)-2-[[4-(3-フルオロベンジルオキシ)ベンジル]アミノ]プロパンアミド(4-((3-fluorobenzyl)oxy)benzyl)-L-alanineCS-484FCE 26743SAFINAMIDSalfenamideSafranamideD4-Safinamide
(2S)-2-((4-((3-fluorophenyl)methoxy)phenyl)methylamino)propanamidefbap methanesulfonateRefChem:57040N04BD03(S)-2-((4-(3-fluorobenzoxy)benzyl)amino)propanamide603-772-2(S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamideXadago

データベース識別子

CAS
133865-89-1
PubChem CID
131682
DTXSID
DTXSID601010282
ChEMBL
CHEMBL396778
ChEBI
CHEBI:134718
UNII
90ENL74SIG
EC Number
603-772-2
Nikkaji
J621.455J

物性

構造計算による物性補完中

XLogP
2.2
極性表面積
64.4 Ų
水素結合供与体数
2
水素結合受容体数
4
回転可能結合数
7
重原子数
22
形式電荷
0
複雑度
346

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Nervous system -> Anti-parkinson drugs

Human Drugs · 3 件

Breastfeeding; Lactation; Antiparkinson Agents; Monoamine Oxidase Inhibitors;

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

物理化学的性質

融点
208 · 208-212°
沸点
476.7 · 476.7±40.0 °C(Predicted)
比重(密度)
1.189 · 1.189±0.06 g/cm3(Predicted)
貯蔵温度
2 · under inert gas (nitrogen or Argon) at 2–8 °C
溶解性
DMSO に可溶 (最大 50 mg/ml)。
外見
個体
酸解離定数(Pka)
16.03 · 16.03±0.50(Predicted)
色
白い
Merck
14 · 14,8315
安定性
-20 °C · -20°C の DMSO 溶液で最大 3 か月間保存できます。
InChI
InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (90.5%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P264+P265, P270, P273, P280, P301+P316, P305+P354+P338, P317, P321, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 42 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationREACH registered substance: Propanamide, 2-(((4-((3-fluorophenyl)methoxy)phenyl)methyl)amino)-, (S)- (EC: 603-772-2)
Hazard Classes and CategoriesAcute Tox. 3 (90.5%)

毒性情報

Hepatotoxicity · 1 件

Safinamide has been reported to cause serum enzyme elevations in a small proportion of patients treated long term, although the abnormalities were usually mild and self-limiting and were usually no more frequent than with placebo or comparator agents. Safinamide has not been implicated in cases of acute liver injury, but such instances have been reported with nonspecific MAO inhibitors.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

rtecs
TX1457385
hs_code
2924.29.7790

化学と産業

薬理情報

ATC Code · 3 件

N04BD03

N - Nervous system

QN - Nervous system

Protein Binding88–90%
Mechanism of Action · 1 件

Safinamide is a unique molecule with multiple mechanisms of action and a very high therapeutic index. It combines potent, selective, and reversible inhibition of MAO-B with blockade of voltage-dependent Na+ and Ca2+ channels and inhibition of glutamate release. Safinamide has neuroprotective and neurorescuing effects in MPTP-treated mice, in the rat kainic acid, and in the gerbil ischemia model.

Biological Half-Life22 h
Metabolism/Metabolites · 1 件

The principal step is mediated by amidases which have not been identified, and produces safinamide acid. It is also metabolized to O-debenzylated safinamide and N-delkylated amine. The N-dealkylated amine is then oxidized to a carboxylic acid and finally glucuronidated. Dealkylation reactions are mediated by cytochrome P450s (CYPs), especially CYP3A4. Safinamide acid binds to organic anion transporter 3 (OAT3), but no clinical relevance of this interaction has been determined. Safinamide also binds to ABCG2 transiently. No other transporter affinities have been found in preliminary studies.

FDA Pharmacological Classification · 6 件

90ENL74SIG

SAFINAMIDE

Established Pharmacologic Class [EPC] - Monoamine Oxidase Type B Inhibitor

Mechanisms of Action [MoA] - Monoamine Oxidase-B Inhibitors

Mechanisms of Action [MoA] - Breast Cancer Resistance Protein Inhibitors

Safinamide is a Monoamine Oxidase Type B Inhibitor. The mechanism of action of safinamide is as a Monoamine Oxidase-B Inhibitor and Breast Cancer Resistance Protein Inhibitor.

Absorption, Distribution and Excretion · 4 件

Rapid with peak plasma concentrations ranging from 2 to 4 h, total bioavailability is 95%. Food prolonged the rate and did not affect the extent of absorption of safinamide.

関連反応

16 件
反応記録を作成
HRID 41736 の反応式
HRID 41736反応物として
HRID 41737 の反応式
HRID 41737反応物として
HRID 41738 の反応式
HRID 41738生成物として
HRID 41740 の反応式
HRID 41740生成物として
HRID 41741 の反応式
HRID 41741反応物として
HRID 83473 の反応式
HRID 83473反応物として
HRID 83474 の反応式
HRID 83474反応物として
HRID 83475 の反応式
HRID 83475生成物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
InChIKey
NEMGRZFTLSKBAP-LBPRGKRZSA-N
SMILES
C(N)(=O)[C@@H](NCC1=CC=C(OCC2=CC=CC(F)=C2)C=C1)C

76% renal, 1.5% faeces

1.8 litres/kg

total oral clearance of plasma , which accounts for parent safinamide as well as metabolites, was on average only 17.53 ± 2.71 ml/h × kg

応用分野 · 1 件

来歴Safinamide is an α-aminoamide derivative with a multimodal mechanism of action involving both dopaminergic and non-dopaminergic properties. It increases levels of available dopamine through dopamine reuptake inhibition andMAO-B inhibition. It is a potent and reversible inhibitor of MAO-B, with significantly greater selectivity for MAO-B over MAO-A than selegiline and rasagiline. However, it also has an important and novel mode of action that involves blockade of Na+ channels andmodulation of Ca2+ channels that inhibits glutamate release and therefore may provide a level of cognitive improvement and neuroprotection. Homeostatic interactions between dopamine and glutamate are central to the normal physiology of the basal ganglia. In PD, this relationship is altered, resulting in upregulation of cortico-striatal glutamatergic function in l-dopa-induced dyskinesia. Any drug that can counteract such unbalance in glutamate function is potentially useful in controlling dyskinesias. Safinamide was originated by Farmitalia Carlo Erba, a company that was later purchased by Pharmacia. Newron Pharmaceuticals was established as a spin-off of Pharmacia in 1999 and acquired safinamide rights and intellectual property from Pharmacia Corporation. Newron originally granted Serono exclusive worldwide rights to develop, manufacture, and commercialize safinamide in 2006. However, in October 2011, Merck Serono agreed to return full global rights for safinamide to Newron. Newron then finalized a strategic collaboration and license agreement with Zambon for the worldwide development and commercialization of safinamide.

上流・下流製品情報

上流原料

L-アラニンアミド(S,E)-2-((4-((3-fluorobenzyl)4-(3-フルオロベンジルオキシ)ベンズアルデヒドL-アラニンアミド塩酸塩水素化ほう素カリウムメタノール